Endo International PLC (NASDAQ:ENDP)‘s stock had its “hold” rating reissued by investment analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Tuesday, August 8th. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q3 2017 earnings at $0.65 EPS, Q4 2017 earnings at $0.71 EPS, FY2017 earnings at $3.52 EPS, FY2018 earnings at $3.23 EPS, FY2019 earnings at $3.48 EPS, FY2020 earnings at $3.67 EPS and FY2021 earnings at $3.86 EPS.
Several other analysts also recently weighed in on ENDP. Canaccord Genuity reiterated a “hold” rating and set a $14.00 price target on shares of Endo International PLC in a research note on Tuesday, April 11th. Mizuho reiterated a “buy” rating and set a $18.00 price target (up previously from $17.00) on shares of Endo International PLC in a research note on Thursday, April 13th. Vetr downgraded Endo International PLC from a “strong-buy” rating to a “hold” rating and set a $11.34 price target on the stock. in a research note on Thursday, April 27th. BMO Capital Markets reiterated a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a research note on Monday, May 1st. Finally, Zacks Investment Research upgraded Endo International PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, May 2nd. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company. Endo International PLC currently has an average rating of “Hold” and a consensus price target of $14.75.
Endo International PLC (NASDAQ:ENDP) traded up 1.04% during midday trading on Tuesday, hitting $8.72. The company had a trading volume of 5,294,100 shares. The stock’s market capitalization is $1.95 billion. The stock has a 50 day moving average price of $10.47 and a 200-day moving average price of $11.43. Endo International PLC has a 52 week low of $7.41 and a 52 week high of $24.93.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.86 EPS. On average, equities analysts predict that Endo International PLC will post $3.52 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Endo International PLC (NASDAQ:ENDP) Rating Reiterated by Oppenheimer Holdings, Inc.” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/19/endo-international-plc-nasdaqendp-given-hold-rating-at-oppenheimer-holdings-inc-updated.html.
In other news, COO Terrance J. Coughlin bought 20,000 shares of Endo International PLC stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $7.70 per share, with a total value of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Paul Campanelli bought 6,500 shares of Endo International PLC stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $7.71 per share, with a total value of $50,115.00. Following the acquisition, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at $1,647,010.20. The disclosure for this purchase can be found here. Insiders have acquired 36,000 shares of company stock valued at $279,460 in the last three months. Insiders own 0.50% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. First Quadrant L P CA bought a new stake in Endo International PLC during the first quarter valued at approximately $24,556,000. OppenheimerFunds Inc. boosted its stake in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Diamond Hill Capital Management Inc. bought a new stake in Endo International PLC during the second quarter valued at approximately $5,454,000. Finally, Ameriprise Financial Inc. boosted its stake in Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares in the last quarter. 92.27% of the stock is owned by hedge funds and other institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
